FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burd	len							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Socks David A				<u>C</u> A	2. Issuer Name and Ticker or Trading Symbol CADENCE PHARMACEUTICALS INC CADX]									k all applic Directo Officer	able)	g Pers	Other (s	% Owner ner (specify	
(Last) (First) (Middle) C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 03/18/2009										below)		VP	below)	aliaabla	
(Street) SAN DIEGO CA 92130 (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution D			ed 3. Date, Transacti Code (Ins						5. Amou 4 and Securitie Benefici		s Illy ollowing	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code V		Amount	(A) or (D) Pric		!	Transacti (Instr. 3 a	tion(s)			(11150.4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate, Tr	Code (Ins				6. Date Exercisa Expiration Date (Month/Day/Yea		e Amount of		of s ng e	D	. Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i i illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				C	ode	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
stock option (right to buy)	\$8.35	03/18/2009			A		60,000		(1)	0	3/17/2019	common stock	60,000	0	(2)	60,000	0	D	

Explanation of Responses:

1. 25% of the number of shares of common stock subject to the option vest one year after the date of grant, and 1/48th of the original number of shares of common stock subject to the option vest on the first day of each full month thereafter.

Remarks:

Hazel M. Aker Attorney-in-fact 03/20/2009

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} Not applicable to this transaction